Abstract 2056P
Background
The wider availability of oncological treatment and the improved survival of cancer patients have increased the frequency of emergency consultations and their impact on healthcare. The aim of this study was to investigate the variables that influence hospital admission, re-consultation and clinical outcomes among oncology patients who seek emergency care.
Methods
Single-center, observational and prospective study. We analyzed a sample of 554 oncology patients who consulted in the Emergency Deparment during regular office hours between March-22 and March-23. Statistics: Chi-squared test to assess association between variables. Kaplan-Meier curves and log-rank test for survival analysis. Significance level: p-value <=0.05.
Results
The baseline characteristics of the study participants were: 50.2% females, 21.5% lung cancer, 68.8% stage IV, 25.8% consulted for digestive symptoms, 37% were hospitalized and 16.4% reconsulted in the following 15 days. The overall median survival was 54 weeks. Factors that were associated with a higher likelihood of hospitalization were lung cancer (26.9% of admissions), stage IV (80.7%), monotherapy chemotherapy (CT) (36.3%), first-line treatment for metastatic disease (40.9%), ECOG 2 (36.8%), digestive symptoms as reason for consultation (29.2%) and complications secondary to the tumor itself as definitive diagnosis (32.2%). Factors significantly associated with a higher likelihood of reconsultation within the following 15 days were lung cancer (19.3% of reconsultations), monotherapy CT (38.6%), ECOG 1 (42.1%) and infectious pathology and complications secondary to the tumor itself (28.1% each one). Factors significantly associated with lower overall survival were hospital admission (median: 16 weeks, 95% CI 3.7-28.2), diagnosis of complications secondary to the tumor itself (median: 11 weeks, 95% CI 10.3 - 23.6) and reconsultation (median: 17 weeks, 95% CI 10.3-23.6).
Conclusions
Among oncology patients admitted to the Emergency department, complications secondary to the underlying oncological disease represent the most relevant variable in the field of oncological emergencies due to their impact on the likelihood of hospitalization, reconsultation and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Sanofi, Lundbeck, Angelini. M.A. Ivars: Financial Interests, Personal, Speaker, Consultant, Advisor: Ipsen Pharma, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06